Bellevue Group Ag Esperion Therapeutics, Inc. Transaction History
Bellevue Group Ag
- $5.93 Billion
- Q3 2024
A detailed history of Bellevue Group Ag transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Bellevue Group Ag holds 9,944,064 shares of ESPR stock, worth $22.7 Million. This represents 0.28% of its overall portfolio holdings.
Number of Shares
9,944,064
Previous 9,944,064
-0.0%
Holding current value
$22.7 Million
Previous $22.1 Million
25.68%
% of portfolio
0.28%
Previous 0.37%
Shares
23 transactions
Others Institutions Holding ESPR
# of Institutions
206Shares Held
128MCall Options Held
1.67MPut Options Held
930K-
Wasatch Advisors Inc Salt Lake City, UT23.3MShares$53.2 Million0.19% of portfolio
-
Black Rock Inc. New York, NY14MShares$31.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA13MShares$29.7 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY6.58MShares$15 Million3.65% of portfolio
-
Geode Capital Management, LLC Boston, MA4.33MShares$9.88 Million0.0% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $152M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...